Jessica Fye
Stock Analyst at JP Morgan
(3.63)
# 896
Out of 4,667 analysts
174
Total ratings
48.11%
Success rate
6.64%
Average return
Main Sectors:
Stocks Rated by Jessica Fye
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $510 → $503 | $451.23 | +11.47% | 6 | Nov 5, 2024 | |
| MRNA Moderna | Maintains: Underweight | $70 → $59 | $36.94 | +59.72% | 10 | Nov 4, 2024 | |
| BNTX BioNTech SE | Maintains: Neutral | $125 → $124 | $102.14 | +21.40% | 9 | Nov 4, 2024 | |
| ITCI Intra-Cellular Therapies | Maintains: Overweight | $81 → $89 | $85.64 | +3.92% | 7 | Nov 4, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $110 → $109 | $62.56 | +74.23% | 3 | Oct 30, 2024 | |
| INCY Incyte | Maintains: Neutral | $65 → $71 | $71.05 | -0.07% | 5 | Oct 30, 2024 | |
| ALKS Alkermes | Maintains: Neutral | $32 → $26 | $27.91 | -6.84% | 6 | Oct 25, 2024 | |
| ASND Ascendis Pharma | Maintains: Overweight | $180 → $174 | $124.38 | +39.89% | 7 | Oct 23, 2024 | |
| BGNE BeiGene | Maintains: Overweight | $200 → $235 | $194.26 | +20.97% | 4 | Oct 22, 2024 | |
| DNLI Denali Therapeutics | Maintains: Overweight | $29 → $28 | $24.42 | +14.66% | 4 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $16.24 | +84.73% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $74 | $72.67 | +1.83% | 5 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $52 → $57 | $45.76 | +24.56% | 11 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $50 → $55 | $35.40 | +55.37% | 2 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $248 → $280 | $248.79 | +12.54% | 3 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $190 → $202 | $119.24 | +69.41% | 3 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $66 | $32.42 | +103.58% | 4 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $54 | $56.07 | -3.69% | 5 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $39 | $43.69 | -10.73% | 3 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $300 | $364.33 | -17.66% | 14 | May 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $13 | $11.31 | +14.94% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $17 | $16.86 | +0.83% | 3 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $1.00 | - | 7 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $8.88 | - | 2 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | n/a | $2.41 | - | 9 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $0.49 | - | 6 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Overweight | $10 | $7.30 | +36.99% | 5 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $76 | $40.14 | +89.34% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $17 → $20 | $0.31 | +6,457.38% | 2 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.01 | - | 2 | Aug 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.52 | +1,347.37% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 | $0.81 | +766.98% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $27 | $18.46 | +46.26% | 5 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.22 | - | 4 | Mar 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $8.06 | - | 3 | Feb 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.88 | - | 4 | Feb 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $9.08 | - | 1 | Feb 8, 2018 |
Vertex Pharmaceuticals
Nov 5, 2024
Maintains: Overweight
Price Target: $510 → $503
Current: $451.23
Upside: +11.47%
Moderna
Nov 4, 2024
Maintains: Underweight
Price Target: $70 → $59
Current: $36.94
Upside: +59.72%
BioNTech SE
Nov 4, 2024
Maintains: Neutral
Price Target: $125 → $124
Current: $102.14
Upside: +21.40%
Intra-Cellular Therapies
Nov 4, 2024
Maintains: Overweight
Price Target: $81 → $89
Current: $85.64
Upside: +3.92%
BioMarin Pharmaceutical
Oct 30, 2024
Maintains: Overweight
Price Target: $110 → $109
Current: $62.56
Upside: +74.23%
Incyte
Oct 30, 2024
Maintains: Neutral
Price Target: $65 → $71
Current: $71.05
Upside: -0.07%
Alkermes
Oct 25, 2024
Maintains: Neutral
Price Target: $32 → $26
Current: $27.91
Upside: -6.84%
Ascendis Pharma
Oct 23, 2024
Maintains: Overweight
Price Target: $180 → $174
Current: $124.38
Upside: +39.89%
BeiGene
Oct 22, 2024
Maintains: Overweight
Price Target: $200 → $235
Current: $194.26
Upside: +20.97%
Denali Therapeutics
Oct 11, 2024
Maintains: Overweight
Price Target: $29 → $28
Current: $24.42
Upside: +14.66%
Oct 8, 2024
Initiates: Overweight
Price Target: $30
Current: $16.24
Upside: +84.73%
Oct 3, 2024
Maintains: Overweight
Price Target: $72 → $74
Current: $72.67
Upside: +1.83%
Sep 19, 2024
Downgrades: Neutral
Price Target: $52 → $57
Current: $45.76
Upside: +24.56%
Aug 26, 2024
Maintains: Neutral
Price Target: $50 → $55
Current: $35.40
Upside: +55.37%
Aug 26, 2024
Maintains: Neutral
Price Target: $248 → $280
Current: $248.79
Upside: +12.54%
Aug 19, 2024
Maintains: Overweight
Price Target: $190 → $202
Current: $119.24
Upside: +69.41%
Jul 10, 2024
Maintains: Overweight
Price Target: $70 → $66
Current: $32.42
Upside: +103.58%
Jul 9, 2024
Maintains: Overweight
Price Target: $47 → $54
Current: $56.07
Upside: -3.69%
Jun 18, 2024
Maintains: Overweight
Price Target: $31 → $39
Current: $43.69
Upside: -10.73%
May 21, 2024
Maintains: Overweight
Price Target: $280 → $300
Current: $364.33
Upside: -17.66%
Mar 26, 2024
Maintains: Neutral
Price Target: $6 → $13
Current: $11.31
Upside: +14.94%
Mar 19, 2024
Maintains: Neutral
Price Target: $15 → $17
Current: $16.86
Upside: +0.83%
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $1.00
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $8.88
Upside: -
Nov 20, 2023
Reinstates: Neutral
Price Target: n/a
Current: $2.41
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $0.49
Upside: -
Nov 20, 2023
Reinstates: Overweight
Price Target: $10
Current: $7.30
Upside: +36.99%
Apr 19, 2023
Maintains: Overweight
Price Target: $65 → $76
Current: $40.14
Upside: +89.34%
Mar 8, 2022
Upgrades: Overweight
Price Target: $17 → $20
Current: $0.31
Upside: +6,457.38%
Aug 20, 2021
Downgrades: Underweight
Price Target: n/a
Current: $3.01
Upside: -
Apr 19, 2021
Initiates: Overweight
Price Target: $22
Current: $1.52
Upside: +1,347.37%
Jan 29, 2021
Upgrades: Neutral
Price Target: $7
Current: $0.81
Upside: +766.98%
May 12, 2020
Maintains: Overweight
Price Target: $32 → $27
Current: $18.46
Upside: +46.26%
Mar 11, 2019
Downgrades: Underweight
Price Target: n/a
Current: $2.22
Upside: -
Feb 28, 2019
Downgrades: Underweight
Price Target: n/a
Current: $8.06
Upside: -
Feb 14, 2018
Downgrades: Underweight
Price Target: n/a
Current: $0.88
Upside: -
Feb 8, 2018
Downgrades: Neutral
Price Target: n/a
Current: $9.08
Upside: -